RAIN THERAPEUTICS
Rain Therapeutics develops targeted therapies for patients with cancer. We begin by identifing cancers with a single, and clear, oncogenic driver and evaluating sub-populations of cancer populations with an unmet need, where standards of care are ineffective. Our global scientific and thought-leader network drives our asset and technology identification to match these cancers with small molecule therapeutics targeted at treating specific cancer mutations.
RAIN THERAPEUTICS
Industry:
Biotechnology Health Care Therapeutics
Founded:
2017-01-01
Address:
Fremont, California, United States
Country:
United States
Website Url:
http://www.rainthera.com
Total Employee:
1+
Status:
Active
Contact:
+1 510-953-5559
Total Funding:
82.36 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default LetsEncrypt Apple Mobile Web Clips Icon Amazon IPv6 Google Apps For Business Google Maps
Similar Organizations
Cradle Genomics
Cradle Genomics is a creator of a novel prenatal testing methodology
Topokine Therapeutics
Topokine is a Boston-based, clinical-stage biotechnology company.
Current Advisors List
Advisor
Current Employees Featured
Richard Bryce Chief Medical Officer @ Rain Therapeutics
Chief Medical Officer
2021-04-01
Dharmendra Singh Senior Scientist @ Rain Therapeutics
Senior Scientist
2020-10-01
Avanish Vellanki Chairman & Ceo @ Rain Therapeutics
Chairman & Ceo
2009-01-01
Founder
Stock Details
Investors List
Samsara BioCapital
Samsara BioCapital investment in Series B - Rain Therapeutics
Logos Capital
Logos Capital investment in Series B - Rain Therapeutics
Cormorant Asset Management
Cormorant Asset Management investment in Series B - Rain Therapeutics
Perceptive Advisors
Perceptive Advisors investment in Series B - Rain Therapeutics
Boxer Capital
Boxer Capital investment in Series B - Rain Therapeutics
Janus Henderson Investors
Janus Henderson Investors investment in Series B - Rain Therapeutics
BVF Partners
BVF Partners investment in Series B - Rain Therapeutics
University of Auckland Inventors Fund
University of Auckland Inventors Fund investment in Series A - Rain Therapeutics
Perceptive Advisors
Perceptive Advisors investment in Series A - Rain Therapeutics
Biotechnology Value Fund
Biotechnology Value Fund investment in Series A - Rain Therapeutics
Official Site Inspections
http://www.rainthera.com Semrush global rank: 3.59 M Semrush visits lastest month: 4.01 K
- Host name: aacb0a264e514dd48.awsglobalaccelerator.com
- IP address: 99.83.190.102
- Location: Seattle United States
- Latitude: 47.54
- Longitude: -122.3032
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98108
More informations about "Rain Therapeutics"
Rain Oncology
Rain Oncology develops innovative, targeted therapies to help patients with cancer get their life back. We focus on cancers where we can genetically identify patients most likely to benefit …See details»
About Us - Rain Oncology
Rain Oncology was founded in 2017 as a precision oncology company leveraging a deep scientific knowledge of drug mechanism and designing clinical trials with the most appropriate …See details»
Clinical Trials - Rain Oncology
National Organization for Rare Disorders Basket Study The MANTRA-2 trial is designed to evaluate the safety and efficacy of milademetan in patients with advanced or metastatic solid …See details»
Rain Oncology - Crunchbase Company Profile & Funding
Rain Oncology Inc. is a precision oncology company developing therapies that target oncogenic drivers to genetically select patients it believes will most likely benefit. An oral small molecule …See details»
RAIN THERAPEUTICS INC. - Orphanet
RAIN THERAPEUTICS INC. The documents contained in this website are presented for information purposes only. The material is in no way intended to replace professional medical …See details»
Rain Oncology - LinkedIn
Rain Oncology is a clinical-stage company researching, developing and translating innovative targeted therapies for patients with cancer to help provide them hope to get their lives back. …See details»
Rain Therapeutics Company Profile - Office Locations ... - Craft
Jan 26, 2024 · Rain Therapeutics is a biotechnology company focused on developing small molecule targeted therapeutics for cancer patients. Its approach includes using a tumor …See details»
Rain Oncology Company Profile 2024: Stock Performance
Rain Oncology Inc is a late-stage precision oncology company developing therapies that target oncogenic drivers for which it is able to genetically select patients it believes will likely benefit. …See details»
Rain Therapeutics Closes $63 Million Series B Financing
Rain Therapeutics Inc., a privately-held, clinical stage biotechnology company focused on targeted therapies for patients with cancer, has closed a $63 million Series B financing.See details»
Avanish Vellanki - CEO and Cofounder at Rain Therapeutics - The …
About. Avanish Vellanki is the CEO and Cofounder at Rain Therapeutics.Prior to this, they served as the Senior Vice President, Chief Business Officer at Aptose Biosciences, Inc. from …See details»
Rain Therapeutics - Work in biotech
Rain Therapeutics is developing targeted therapies for cancer patients. Precision oncology prioritizes pairing drugs with cancer patients and underlies Rain’s development philosophy.See details»
Organization: Rain Therapeutics - Cbonds.com
Rain Therapeutics. Information about the issuer. News and credit ratings. . Tables with accounting and financial reporting.See details»
Sri Ranga Yarlagadda - Director, Corporate Development at
Ranga Yarlagadda has a diverse work experience spanning multiple industries and roles. Ranga is currently serving as the Director of Corporate Development at Rain Oncology since July 2022.See details»
Rain Therapeutics Announces First Patient Dosed in Phase 2
Mar 19, 2019 · Rain Therapeutics Inc. is a privately-held biotechnology company developing biomarker-driven small molecule therapeutics for patients with cancer. Rain’s lead program, …See details»
Rain Therapeutics Appoints Robert Doebele, M.D., Ph.D. as President
NEWARK, Calif., May 20, 2021 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (“Rain”), a clinical-stage company developing precision oncology therapeutics, today announced the …See details»
Rain Therapeutics Announces License Agreement for the …
Rain Therapeutics Inc. recently announced the signing of an exclusive, worldwide license agreement of a Drexel University research program to Rain for small molecule inhibitors of …See details»
Rain Oncology Inc - Cruelty Free Investing
Rain Therapeutics Inc., a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States. Its lead product candidate is …See details»
Pipeline - Rain Oncology
Establishing the clinical profile of milademetan for patients with TP53 wildtype tumors. Rain is building a pipeline that’s focused on genetically selecting the patients most likely to benefit …See details»
Ranga Yarlagadda - Rain Oncology - LinkedIn
REF is a global organization that brings together business leaders in peer advisory groups to enhance their leadership skills and business strategies.See details»
Rain Therapeutics Reports Fourth Quarter and Full Year 2021 …
NEWARK, Calif., March3, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (Rain), a late-stage company developing precision oncology therapeutics, today …See details»